The 4:47 PM Phone Call That Costs Frisco Professionals Thousands

The call came in at 4:47 PM on a Wednesday — golden-hour light spilling through the glass of an office tower off the Dallas North Tollway. The applicant had just settled into his chair. Two-point-one million dollars in twenty-year term, riding shotgun on a buy-sell agreement with his business partner. He thought he was approved. The call was the underwriter.

“We need to talk about the Wegovy.”

He hadn’t lied. He’d checked the prescription medication box and listed it. He hadn’t injected in two weeks — pharmacy shortage. He didn’t have diabetes. He’d dropped 32 pounds and his blood pressure was the best of his life. So why was the underwriter calling? Because the carrier his prior agent had picked was a single-brand captive that hadn’t built a modern GLP-1 underwriting protocol yet. The default response, by spreadsheet, was “postpone six months” or “table rate at +75%.” The “final” premium had just tripled. That phone call happens every week in Collin County — and most of the time it could have been avoided by knowing which carrier to approach first. This guide is how you avoid it. Start with our North Texas life insurance hub if you want the bird’s-eye view; otherwise, keep reading.

What Underwriters Actually See When You’re on a GLP-1

First principle: life insurance underwriting is risk classification, not character judgment. The underwriter is answering one question — what is the probability this applicant survives the term I’m pricing? The carrier feeds that probability into actuarial tables, sets a price, and either accepts, rates up, postpones, or declines. Knowing exactly what they see makes the whole process less mysterious.

When you apply while taking a GLP-1 — Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, or any newer entrant — four signals reach the underwriter’s desk before you finish lunch:

• The pharmacy database hit. Carriers query a prescription history database that returns 5–10 years of pharmacy fills. GLP-1 prescriptions show up the same day.
• The MIB file. The MIB Group database cross-references every life insurance application you’ve made in North America. If a previous carrier postponed or rated you for a GLP-1, the next carrier sees it.
• The exam labs. Hemoglobin A1c, fasting glucose, lipid panel, BMI. GLP-1 users often show improved numbers — that helps.
• The Attending Physician Statement (APS) if anything flags. This is the actual chart note from your prescribing doctor explaining why you’re on the drug.

That fourth signal is where the whole conversation pivots. Underwriters split GLP-1 users into three buckets, and each bucket gets a different ride:

• Type 2 diabetes use — long-standing on-label use. Often Standard or mild table rating when A1c is controlled.
• Cardiometabolic / chronic weight management use — the on-label Wegovy/Zepbound indication. Outcome depends on baseline BMI, comorbidities, and time on therapy with measurable improvement.
• Cosmetic / off-label weight loss — the trickiest bucket. Some carriers handle it gracefully now. Others still treat it like a flag they don’t have a checkbox for.

The carrier that processes your file determines which bucket they read you into. And that’s where the independent insurance agent earns their keep — by knowing those buckets carrier by carrier, before you sign anything.

The Texas Reality: Disclosure, Contestability & The SELECT Trial Shift

Texas has skin in this game like few other states. According to CDC obesity prevalence data, Texas adult obesity sits at roughly 35% — among the highest in the country. Adult diabetes prevalence is about 12.6%. That means GLP-1 prescription volume across the state is enormous and still climbing — and Frisco, Plano, McKinney, and Prosper sit at the leading edge of that wave because Collin County’s higher household income makes the cash-pay GLP-1 channel accessible to people who don’t meet a strict diabetes diagnosis.

Now overlay the Texas Insurance Code. Under Texas law, a life insurance policy is contestable for two years from the issue date. During that window, if the insurer can prove a material misrepresentation on the application, they can void the contract and refund premiums — leaving the beneficiary with nothing. The Texas Department of Insurance regulates this entire process. Failing to disclose a GLP-1 prescription is a textbook material misrepresentation. The carrier doesn’t need to prove you intended to deceive; they just need to show the prescription existed and would have affected underwriting. Proverbs 22:3 puts it plainly: “A prudent man foreseeth the evil, and hideth himself: but the simple pass on, and are punished.” In insurance, the prudent move is the disclosed move.

Here’s the good news the headlines have missed. In late 2023, the New England Journal of Medicine published the SELECT trial results for semaglutide, showing a 20% reduction in major adverse cardiovascular events among overweight patients without diabetes. That study moved the actuarial conversation. By 2025, several reinsurers had quietly issued updated guidance to their cedents allowing better classifications for stable GLP-1 users with documented cardiovascular benefit. Carriers are catching up at different speeds. The ones who’ve absorbed the new data treat GLP-1 use very differently than the ones who haven’t. If you applied two years ago and got rated, the answer may have changed — especially if you’ve been stable on therapy with improving labs. This is one of the central themes when we walk Frisco clients through applying with existing health conditions.

The Four Myths That Cost Frisco Applicants Real Money

• Myth: “Just leave the GLP-1 off the application — the carrier won’t find out.”
  Reality: They will. The pharmacy database fires within hours. The MIB hit shows up on the first cross-reference. The exam may flag improved labs that don’t match your weight history. Discovery during contestability voids the policy. Discovery after contestability still triggers an investigation if the claim is large — one of the top claim denial reasons we see. You risk the entire death benefit to save a fraction on premium. Bad math.
• Myth: “I’ll stop Ozempic, wait six months, and then apply.”
  Reality: The Attending Physician Statement still shows the prescription history. The pharmacy database still shows the fills. Worse, many people regain weight after discontinuation — meaning you apply heavier than you would have on the drug, plus you’ve lost the cardiovascular benefit signal. The medically and financially smarter move is usually to apply while stable on therapy, with documented improvement.
• Myth: “I was declined once, so I can’t get life insurance anywhere.”
  Reality: A decline from one carrier is a data point, not a verdict. Carriers vary wildly in their GLP-1 stance. The right move is an informal inquiry — a pre-application, anonymous shopping of your case to multiple underwriters before you formally apply, so the next “no” doesn’t follow you on your MIB file.
• Myth: “If I’m overweight, I shouldn’t bother applying.”
  Reality: Most healthy Frisco professionals on GLP-1’s qualify. The question is which carrier and which rate class. Even a table-rated policy is usually a sound transaction when you measure premium against the protection it buys. Walk through what really moves life insurance pricing before you self-disqualify.

Carrier Appetite: How the Same Applicant Gets Five Different Answers

Here’s the rough lay of the land across the carrier categories The Agent’s Office® works with. This is directional — actual outcomes depend on the full picture (age, BMI, A1c, comorbidities, family history) — and guidelines change quarterly as more carriers absorb modern GLP-1 underwriting data. The point of the table isn’t to predict your outcome; it’s to show why carrier selection is the single biggest lever in your premium.

The takeaway: the same applicant can be Standard at one carrier and declined at another. The agent’s job is to know which carrier sits where on this spectrum before the application is signed. That’s the entire ballgame.

The Agent’s Office® Workflow for GLP-1 Cases

We are an independent agency. We don’t have to push you toward one carrier’s product. We hold appointments with 75+ insurers across personal lines, commercial, and life. When a GLP-1 case lands on our desk, here’s the actual workflow:

• Pre-screen. Before any formal application, we sit with you and document the full picture — diagnosis (if any), drug, dosage history, labs, family history, and lifestyle.
• Informal inquiry. We shop your case anonymously to 3–5 carriers whose current guidelines fit your profile best. Underwriters give us a preliminary opinion before your name ever hits a formal application.
• Strategic application. We submit to the carrier most likely to issue at the best rate class — not the first one whose name you recognize from a TV ad.
• APS choreography. We coordinate with your prescribing physician so the chart notes the carrier receives tell the full, accurate story — A1c trajectory, weight loss, cardiovascular improvement, time on therapy.
• Backup carrier ready. If the first application doesn’t land where we expect, we have a Plan B carrier teed up — not a six-month wait.

That workflow is the difference between paying $90/month and paying $230/month for the same death benefit. In some cases it’s the difference between approved and declined. We’ve placed coverage for Frisco-area clients on Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, and Rybelsus across a wide spectrum of medical pictures. There is no scenario we won’t look at honestly — and if a traditional policy isn’t the right fit today, we’ll show you no-exam life insurance options or a temporary bridge while you build the right application story for next year. Timing matters here too — if you’re still deciding, our note on the right time to apply for life insurance is worth the five minutes.